Preparing for RSV immunisation and surveillance in Europe


Respiratory syncytial virus (RSV) is an infectious disease that can cause severe illness in young children as well as the elderly and people with weakened immune systems. Globally, an estimated 33 million young children are diagnosed with RSV every year, and over 3 million are hospitalised. Currently, there is no vaccine or treatment for RSV, although a number of products are in clinical trials or earlier stages of clinical development.

The aim of PROMISE is to significantly advance our understanding of RSV to aid in the design of public health strategies as well as the development and use of vaccines and therapeutics in both children and older people. It builds on the work of IMI’s RESCEU project, which has delivered significant insights and resources on RSV.

The project plans to address current knowledge gaps on RSV, such as the relationship between RSV infection and school age wheeze and asthma. They will also identify new diagnostic tools and study biological markers of RSV infection. In addition, the project will develop a surveillance network on RSV, a resource that will provide valuable information on respiratory infections in the community. Finally, PROMISE will attempt to evaluate the impact of COVID-19 on the spread of RSV, especially among older adults.

Achievements & News


  Show participants on map
EFPIA companies
  • Astrazeneca AB, Södertälje, Sweden
  • Glaxosmithkline Biologicals SA, Rixensart, Belgium
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novavax Inc, Gaithersburg, United States
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi Pasteur SA, Lyon, France
Universities, research organisations, public bodies, non-profit groups
  • Fondazione PENTA - for the treatment and care of children with HIV-ONLUS, Padova, Italy
  • Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana, Valencia, Spain
  • Imperial College Of Science Technology And Medicine, London, United Kingdom
  • Martin-Luther-Universitat Halle-Wittenberg, Halle (Saale), Germany
  • Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands
  • Servizo Galego De Saude, Santiago de Compostela, Spain
  • Statens Serum Institut, Copenhagen S, Denmark
  • Stichting Nederlands Instituut Voor Onderzoek Van De Gezondheidszorg, Utrecht, Netherlands
  • Terveyden Ja Hyvinvoinnin Laitos, Helsinki, Finland
  • The University Of Edinburgh, Edinburgh, United Kingdom
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
  • Universiteit Antwerpen, Antwerp, Belgium
  • University of Oxford, Oxford, United Kingdom
  • Varsinais-Suomen Hyvinvointialue, Turku, Finland
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Stichting Resvinet, Zeist, Netherlands
  • Teamit Research SL, Barcelona, Spain

NameEU funding in €
Fondazione PENTA - for the treatment and care of children with HIV-ONLUS53 750
Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana67 500
Imperial College Of Science Technology And Medicine305 000
Martin-Luther-Universitat Halle-Wittenberg98 750
Rijksinstituut Voor Volksgezondheid En Milieu358 125
Servizo Galego De Saude67 500
Statens Serum Institut150 000
Stichting Nederlands Instituut Voor Onderzoek Van De Gezondheidszorg129 375
Stichting Resvinet84 375
Teamit Research SL587 125
Terveyden Ja Hyvinvoinnin Laitos170 625
The University Of Edinburgh746 625
Universitair Medisch Centrum Utrecht470 000
Universiteit Antwerpen95 000
University of Oxford203 750
Varsinais-Suomen Hyvinvointialue126 915
Varsinais-Suomen Sairaanhoitopiirin Kuntayhtyma (left the project)29 960
Total Cost3 744 375